170 patents currently held

81 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2027. from the record

Of the 81 now held by other companies, 10 name Adverio Pharma GmbH as their current owner, and 71 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Nov 2027

Next term end

122

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Antibody Drug Conjugates (ADCS) Having Enzymatically Cleavable Groups US 11,660,351

Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.

Ends Mar 2039 · High confidence Also notable

New Substituted Indazoles, Methods for the Production Thereof, Pharmaceutical Preparations That Contain Said New Substituted Indazoles, and Use of Said New Substituted Indazoles to Produce Drugs US 10,308,634

Cited by 22 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2035.

Ends Nov 2035 · High confidence Also notable

2-(MORPHOLIN-4-YL)-1,7-Naphthyridines US 9,549,932

The most cited patent in this portfolio, cited by 29 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2035.

Ends Aug 2035 · High confidence

Formerly held, still cited

Notable

Substituted 5-Fluoro-1H-PYRAZOLOPYRIDINES and Their Use US 8,420,656

Cited by 78 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.

now held by Adverio Pharma GmbH

Ends May 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

3 fees due Nov 19 to 30, 2026 · next Nov 19
8 fees due Dec 4 to 27, 2026 · next Dec 4
4 fees due Jan 4 to 21, 2027 · next Jan 4
2 fees due Feb 1 to 27, 2027 · next Feb 1
3 fees due Mar 8 to 24, 2027 · next Mar 8
5 fees due Apr 1 to 17, 2027 · next Apr 1
4 fees due May 7 to 26, 2027 · next May 7
4 fees due Jun 3 to 30, 2027 · next Jun 3
1 fee due Jul 30, 2027
The maintenance fee for A Substituted Oxopyridine Derivative (US 11,884,660) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
2 fees due Aug 6 to 20, 2027 · next Aug 6
2 fees due Sep 5 to 10, 2027 · next Sep 5
3 fees due Oct 2 to 28, 2027 · next Oct 2
1 fee due Nov 7, 2027
The maintenance fee for Inhibitor of Atr Kinase for Use in a Method of Treating a Hyper-Proliferative Disease (US 11,976,334) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026
4 terms have ended since Aug 16, 2026

What they patent

The 5 largest of its 122 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

New Substituted Indazoles, Methods for the Production Thereof, Pharmaceutical Preparations That Contain Said New Substituted Indazoles, and Use of Said New Substituted Indazoles to Produce Drugs	5 in force	to Nov 2035
2,4,5-Trisubstituted 1,2,4-Triazolones Useful as Inhibitors of Dhodh	4 in force	to Oct 2036
New Gadolinium Chelate Compounds for Use in Magnetic Resonance Imaging	4 in force	to May 2036
Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and uses thereof	4 in force	to Jul 2033
Bicyclically Substituted Uracils and the Use Thereof	4 in force	to May 2033

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,987,261	Substituted Dihydropyrazolones for Treating Cardiovascular and Hematological Diseases In force Term ends Nov 27, 2027 · Medium confidence	In force	Term ends Nov 27, 2027	Medium confidence
US 9,051,316	Substituted 4-ARYL-1,4-Dihydro-1,6-Naphthyridine Amides and Their Use In force Term ends Jun 10, 2028 · High confidence	In force	Term ends Jun 10, 2028	High confidence
US 9,737,488	Pharmaceutical Composition for the Treatment of Cancer In force Term ends Sep 10, 2028 · High confidence	In force	Term ends Sep 10, 2028	High confidence
US 8,916,600	Phenyl and Benzodioxinyl Substituted Indazoles Derivatives In force Term ends May 19, 2029 · High confidence	In force	Term ends May 19, 2029	High confidence
US 8,188,270	Novel Polymorphous Form of 5-Chloro-N-({(5S)-2-OXO-3[4-(3-OXO-4-Morpholinyl)-PHENYL]-1,3-Oxazolidine-5-YL}-METHYL)-2-Thiophene Carboxamide In force Term ends May 20, 2029 · High confidence	In force	Term ends May 20, 2029	High confidence
US 9,035,023	Bombesin Analog Peptide Antagonist Conjugates In force Term ends Aug 13, 2029 · High confidence	In force	Term ends Aug 13, 2029	High confidence
US 8,334,291	Novel Aliphatically Substituted Pyrazolopyridines, and the Use Thereof In force Term ends Dec 8, 2029 · High confidence	In force	Term ends Dec 8, 2029	High confidence
US D748,244	Electronic Autoinjector held by Bayer Pharma Aktiengesellschaft and Olufsen Medicom A/S, Corporation In force Term ends Jan 26, 2030 · High confidence	In force	Term ends Jan 26, 2030	High confidence
US D748,245	Electronic Autoinjector held by Bayer Pharma Aktiengesellschaft and Bang & Olufsen Medicom A/S Corporation In force Term ends Jan 26, 2030 · High confidence	In force	Term ends Jan 26, 2030	High confidence
US 9,084,829	Anti-Mesothelin Immunoconjugates and Uses Therefor held by Bayer Intellectual Property GmbH In force Term ends Apr 16, 2030 · High confidence	In force	Term ends Apr 16, 2030	High confidence

10 of 170 patents shown.

Pro members see all 170.

Pro members: see all 170 patents

Also on record, not counted in the 170: 81 patents in force now held by others · 463 patents ended · 21 applications pending · 361 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Bayer Pharma Aktiengesellschaft